Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase III study on the effect of bortezomib combined with adriamycin [doxorubicin], dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma

X
Trial Profile

A randomized phase III study on the effect of bortezomib combined with adriamycin [doxorubicin], dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Filgrastim; Melphalan; Thalidomide; Vincristine
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Millennium
  • Most Recent Events

    • 14 Dec 2021 Results of Intergroup Analysis from phase III trials, HD4, MM5 and HD6 and European Myeloma Network (EMN) 02/ Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation (HOVON) 95 presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 06 Nov 2019 Results, long term follow up after median 137 months of Bortezomib-based induction and maintenance therapy assessing overall survival in the VAD arm versus PAD arm, released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results (n=354) assessing long term survival of Bortezomib in multiple myeloma in German patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top